{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Strobl MAR"],"funding":["Medical Research Council","U.S. Department of Health &amp; Human Services | NIH | National Cancer Institute","NCI NIH HHS","RCUK | Engineering and Physical Sciences Research Council"],"pagination":["46"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9053239"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["2"],"pubmed_abstract":["<h4>Background</h4>Adaptive therapy aims to tackle cancer drug resistance by leveraging resource competition between drug-sensitive and resistant cells. Here, we present a theoretical study of intra-tumoral competition during adaptive therapy, to investigate under which circumstances it will be superior to aggressive treatment.<h4>Methods</h4>We develop and analyse a simple, 2-D, on-lattice, agent-based tumour model in which cells are classified as fully drug-sensitive or resistant. Subsequently, we compare this model to its corresponding non-spatial ordinary differential equation model, and fit it to longitudinal prostate-specific antigen data from 65 prostate cancer patients undergoing intermittent androgen deprivation therapy following biochemical recurrence.<h4>Results</h4>Leveraging the individual-based nature of our model, we explicitly demonstrate competitive suppression of resistance during adaptive therapy, and examine how different factors, such as the initial resistance fraction or resistance costs, alter competition. This not only corroborates our theoretical understanding of adaptive therapy, but also reveals that competition of resistant cells with each other may play a more important role in adaptive therapy in solid tumours than was previously thought. To conclude, we present two case studies, which demonstrate the implications of our work for: (i) mathematical modelling of adaptive therapy, and (ii) the intra-tumoral dynamics in prostate cancer patients during intermittent androgen deprivation treatment, a precursor of adaptive therapy.<h4>Conclusion</h4>Our work shows that the tumour's spatial architecture is an important factor in adaptive therapy and provides insights into how adaptive therapy leverages both inter- and intra-specific competition to control resistance."],"journal":["Communications medicine"],"pubmed_title":["Spatial structure impacts adaptive therapy by shaping intra-tumoral competition."],"pmcid":["PMC9053239"],"funding_grant_id":["U01 CA232382","EP/L016044/1","U01CA232382","U54CA193489"],"pubmed_authors":["Gallaher J","West J","Robertson-Tessi M","Anderson ARA","Maini PK","Strobl MAR"],"additional_accession":[]},"is_claimable":false,"name":"Spatial structure impacts adaptive therapy by shaping intra-tumoral competition.","description":"<h4>Background</h4>Adaptive therapy aims to tackle cancer drug resistance by leveraging resource competition between drug-sensitive and resistant cells. Here, we present a theoretical study of intra-tumoral competition during adaptive therapy, to investigate under which circumstances it will be superior to aggressive treatment.<h4>Methods</h4>We develop and analyse a simple, 2-D, on-lattice, agent-based tumour model in which cells are classified as fully drug-sensitive or resistant. Subsequently, we compare this model to its corresponding non-spatial ordinary differential equation model, and fit it to longitudinal prostate-specific antigen data from 65 prostate cancer patients undergoing intermittent androgen deprivation therapy following biochemical recurrence.<h4>Results</h4>Leveraging the individual-based nature of our model, we explicitly demonstrate competitive suppression of resistance during adaptive therapy, and examine how different factors, such as the initial resistance fraction or resistance costs, alter competition. This not only corroborates our theoretical understanding of adaptive therapy, but also reveals that competition of resistant cells with each other may play a more important role in adaptive therapy in solid tumours than was previously thought. To conclude, we present two case studies, which demonstrate the implications of our work for: (i) mathematical modelling of adaptive therapy, and (ii) the intra-tumoral dynamics in prostate cancer patients during intermittent androgen deprivation treatment, a precursor of adaptive therapy.<h4>Conclusion</h4>Our work shows that the tumour's spatial architecture is an important factor in adaptive therapy and provides insights into how adaptive therapy leverages both inter- and intra-specific competition to control resistance.","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022","modification":"2026-05-31T07:09:41.578Z","creation":"2025-04-04T07:57:35.452Z"},"accession":"S-EPMC9053239","cross_references":{"pubmed":["35603284"],"doi":["10.1038/s43856-022-00110-x"]}}